FINWIRES · TerminalLIVE
FINWIRES

HKG:9995

7 stories mentioning HKG:9995

Every FINWIRES story that references HKG:9995, newest first.

Asia

RemeGen Gets China Marketing Nod for Telitacicept Injection for IgA Nephropathy Indication

RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and conditional marketing approval for a new indication of Telitacicept Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of IgA nephropathy, or to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

HKG:9995SHA:688331
Asia

RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China

RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and marketing approval for a new indication of Telitacicept for Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The new indication of the drug is for the treatment of Sjögren's syndrome, the biopharmaceutical company said.

HKG:9995SHA:688331
Asia

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a drug registration certificate from China's National Medical Products Administration for a new indication for toripalimab, according to a Hong Kong bourse filing on Thursday.The pharmaceutical company's Shanghai shares dropped by less than 4%, while Hong Kong shares fell by less than 2% during Friday's morning trade.The drug, which trades as Tuoyi, will be allowed for the treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma in combination with disitamab vedotin, an antibody drug conjugate developed by RemeGen (HKG:9995, SHA:688331).

HKG:1877HKG:9995SHA:688180SHA:688331
Asia

RemeGen Invests in Wealth Management Products

RemeGen (HKG:9995, SHA:688331) said it invested in various wealth management products offered by Huatai Securities, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company invested 60 million yuan in a fixed-income product that invests in debt assets, 75 million yuan in another fixed-income product that covers liquid financial instrument, and a further 102 million yuan in a fixed-income product tied to financial products and cash-type assets.The company also invested 216 million yuan in a ten-year product that will be invested in financial products and cash-type assets.The firm said the products will help "revitalize idle funds."

HKG:9995SHA:688331
Asia

RemeGen Swings to Profit in Q1 2026

RemeGen (HKG:9995, SHA:688331) booked 328 million yuan in attributable profit for the first quarter of 2026, swinging from a loss of 254.1 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The biopharmaceutical company's Hong Kong shares were down 2% in late morning trade Wednesday.Earnings per share were 0.58 yuan, compared with a loss of 0.46 year in the prior year period.Operating revenue jumped 25% year on year to 656.2 million yuan, figures showed.

HKG:9995SHA:688331
Asia

RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement

RemeGen (HKG:9995) said it received a $650 million upfront payment from AbbVie under a previously entered global licensing agreement involving RC148, according to a Hong Kong bourse filing Wednesday.The deal also includes milestone payments of up to $4.95 billion and tiered double-digit royalties on overseas sales.RC148 is a bispecific antibody designed to enhance anti-tumor immune responses while inhibiting tumor-driven angiogenesis.

HKG:9995
Asia

RemeGen Drug Approved For Cancer Indication

RemeGen (HKG:9995) said China's drug regulator approved its Disitamab Vedotin for the treatment of a type of bladder cancer, according to a Hong Kong bourse filing Friday.Shares of the firm gained over 4% in morning trade Monday.The drug was approved in combination with toripalimab for the treatment of urothelial carcinoma which expresses the HER2 protein.The approval marks the fifth indication for Disitamab Vedotin in China.

HKG:9995